Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Christopher Bowlus MD

Christopher L. Bowlus MD

Lena Valente Professor of Medicine and Division Chief, Gastroenterology and Hepatology, University of California Davis School of Medicine, Davis, California

Dr. Bowlus is the Lena Valente Professor of Medicine and the Chief of the Division of Gastroenterology and Hepatology at the University of California Davis School of Medicine. He received his medical degree from St. Louis University and completed his post-graduate training in Internal Medicine at the University of California Davis and in Gastroenterology at Yale University before returning to UC Davis as a faculty member in 1998. His research in autoimmune liver diseases includes the first published study of a biologic for the treatment of primary biliary cholangitis (PBC) as well as key studies of the immunopathogenesis of primary sclerosing cholangitis (PSC). He is a member of the Steering Committees for the International PSC Study Group and Chairs the Consortium for Autoimmune Liver Disease (CALiD), a group which he founded and now includes over 20 active institutions studying PSC. He leads multiple clinical trials has been funded by the NIH, CDC, and industry. Dr. Bowlus is a Fellow of the AASLD, AGA, ACP, and RCPE.


Dr. Bowlus reports the following:
  • All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.): Intercept (payment to institution)
  • Grants or contracts from any entity (all paid to institution): 
    • Gilead
    • BMS
    • Cymabay Therapeutics
    • Genfit
    • GSK
    • Mirum
    • Pliant
    • Novartis
    • BiomX
    • Boston Scientific
    • Cour Pharmaceuticals
    • Target Pharmasolutions